NAFDAC orders production of Chloroquine for the clinical trial treatment of Coronavirus  Days after approving Chloroquine productionfor a clinical trial to tackle coronavirus , the Director-General of the National Agency for Food and Drug Administration and Control ( NAFDAC ) , Prof .
Mojisola Adeyeye , says the agency has ordered the manufacturing of Chloroquine for emergency stock for the clinical trial treatment of Coronavirus .
In a statement released this morning , Professor Adeyeye said the old antimalarial is now being repurposed for the clinical trial treatment of novel Coronavirus .
According to her , some countries have started the use of Chloroquine for the treatment of COVID-19 .
Adeyeye said the durg was used in China and was discovered to be efficient and safe in the treatment of COVID-19 associated pneumonia .
" Other researchers in France , US have used the drug for the clinical trial treatment of COVID-19 and they reported effectiveness of the drug .
Lagos State will be starting a clinical trial on chloroquine to evaluate the effectiveness .
" In a very recent publication , chloroquine was reported in a press briefing by the State Council of @ @ @ @ @ @ @ @ @ @ and acceptable safety in treating COVID-19 associated pneumonia in a multi-center clinical trials conducted in China .
" The study involved 10 hospitals in Wuhan , Jingzhou , Guangzhou , Beijing , Shanghai , Chongqing and Ningbo , and 100 patients .
The investigators reported that Chloroquine phosphate is superior to the control in inhibiting the pneumonia associated with COVID-19 , and shortening the course of the disease .
" the statement in part read  " About four weeks ago , I approached a local manufacturing company ( May and Baker ) , a member of Pharmaceutical Manufacturing Group of Manufacturing Association of Nigeria ( PMGMAN ) , whose flagship product in the past was chloroquine to make a batch of the drug for emergency stock .
" The company had NAFDAC approval for the production of the drug as antimalarial many years ago before the discontinuation .
" The Managing Director expressed possible difficulty in getting the API due to the fact that the drug has been discontinued .
He called shortly after that he was able to get the API and was asked to @ @ @ @ @ @ @ @ @ @ people become exposed and infected with the virus .
The batch has been manufactured and the company plans to make more batches if needed .
"  She appealed to Nigerians not to use Chloroquine without the guidance of a medical doctor or clinician for treatment of COVID-19 .
According to her , side effects from the use of Chloroquine includes gastrointestinal upset , blurred vision , headache and pruritis ( itching ) among others .
